Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed-Dose Combination in Participants With Chronic Genotype 1 HCV Infection

Mise à jour : Il y a 4 ans
Référence : NCT02021656

Femme et Homme

Extrait

This study will evaluate the antiviral efficacy of ledipasvir (LDV)/sofosbuvir (SOF) fixed-dose combination (FDC) in treatment-naive and treatment-experienced participants with chronic genotype 1 Hepatitis C Virus (HCV) infection. Participants will receive 12 weeks of treatment and continue assessments during a 24-week follow-up period.


Critère d'inclusion

  • Chronic HCV Infection

Liens